Communiqués Orexo AB

Actions

ORX

SE0000736415

Produits pharmaceutiques

PEA

Temps réel estimé Cboe Europe 13:43:52 08/10/2026			Varia. 5j.	Varia. 1 janv.
6,760 ^SEK	-4,92 %		-48,55 %	-76,48 %

06/10	Interview du directeur général de Orexo, Nikolaj Sørensen, avant l’émission à venir	FW
06/10	Orexo prévoit une augmentation de capital de 250 millions de couronnes suédoises pour financer le développement de médicaments	MT

Communiqués

06/10	Orexo: Withdrawing fair value range	AQ
06/10	Notice of Extraordinary General Meeting of Orexo	AQ
06/10	Orexo resolves on a rights issue of approximately 250 MSEK subject to approval by an extraordinary general meeting and provides a financial update	AQ
29/09	Orexo resubmits NDA for IZIPRY™ to the FDA, a high-dose rescue medication for opioid overdose	AQ
14/09	Orexo: FDA clearance to start pivotal programme	AQ
10/09	BARDA Supports Contract Modification extending the initial Development stage for the OX390 project to end of 2027	AQ
01/09	Fredrik Järrsten resigns as CFO of Orexo AB	AQ
31/08	Orexo: Highlights from DNB Carnegie’s Micro Cap Day	AQ
31/08	Orexo: Reaches a non-binding settlement with DOJ	AQ
31/08	Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice	AQ
17/07	Orexo: Weak Q2, with potential H2 catalysts nearing – Q2 review	AQ
16/07	Orexo : Audiocast (engelska)	PU
16/07	Orexo Q2 2026 Interim Report	AQ
09/06	Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships	AQ
19/05	Orexo: Promising early-stage data	AQ
19/05	Orexo announces positive outcome from an in-vivo study of OX390	AQ
07/05	Report from Orexo AB’s annual general meeting May 7 2026	AQ
29/04	Orexo: Better visibility, few near-term catalysts – Q1 review	AQ
28/04	Orexo : Earnings Call Q1 2026 (engelska)	PU
28/04	Orexo : Earnings Call Q1 2026	PU
28/04	Orexo : Q1 2026 Interim Report MASTER	PU
28/04	Orexo : Q1 2026 Interim Report 2026	PU
28/04	Orexo : Audiocast	PU
28/04	Orexo Q1 2026 Interim Report	AQ
21/04	Invitation to presentation of Orexo´s Q1 2026 Interim Report	AQ